Clinical Radiology
Volume 67, Issue 2 , Pages 95-105 , February 2012

Cardiac MRI in restrictive cardiomyopathy

  • A. Gupta

      Affiliations

    • Department of Cardiovascular Radiology, All India Institute of Medical Sciences, Ansari Nagar, Delhi, India
    • ,
  • G. Singh Gulati

      Affiliations

    • Department of Cardiovascular Radiology, All India Institute of Medical Sciences, Ansari Nagar, Delhi, India
    • Corresponding Author InformationGuarantor and correspondent: G. Singh Gulati, Department of Cardiovascular Radiology, All India Institute of Medical Sciences, Ansari Nagar, Delhi 110029, India. Tel.: +91 11 26594452; fax: +91 11 26588663.
    • ,
  • S. Seth

      Affiliations

    • Department of Cardiology, All India Institute of Medical Sciences, Ansari Nagar, Delhi, India
    • ,
  • S. Sharma

      Affiliations

    • Department of Cardiovascular Radiology, All India Institute of Medical Sciences, Ansari Nagar, Delhi, India

Received 18 August 2010 ,Revised 17 May 2011 ,Accepted 22 May 2011.

References 

  1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842
  2. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336(4):267–276
  3. Sengupta PP, Krishnamoorthy VK, Abhayaratna WP, et al. Disparate patterns of left ventricular mechanics differentiate constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol Cardiovasc Imaging. 2008;1:29–38
  4. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387–1393
  5. Jellis C, Martin J, Narula J, et al. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol. 2010;56(2):89–97
  6. Zerhouni EA, Parish DM, Rogers WJ, et al. Human heart: tagging with MR imaging — a new method for noninvasive assessment of myocardial motion. Radiology. 1988;169(1):59–63
  7. Hancock EW. Differential diagnosis of restrictive cardiomyopathy and constrictive pericarditis. Heart. 2001;86(3):343–349
  8. Giorgi B, Mollet NR, Dymarkowski S, et al. Clinically suspected constrictive pericarditis: MR imaging assessment of ventricular septal motion and configuration in patients and healthy subjects. Radiology. 2003;228(2):417–424
  9. Desai HV, Aronow WS, Peterson SJ, et al. Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev. 2010;18(1):1–11
  10. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med. 1998;91(2):141–157
  11. Röcken C, Peters B, Juenemann G, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002;106(16):2091–2097
  12. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008–1010
  13. Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987;59(5):418–422
  14. Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004;43(3):410–415
  15. Jagia P, Gulati GS, Sharma S. Cardiac magnetic resonance in the assessment of cardiomyopathies. Indian J Radiol Imaging. 2007;17(2):109–119
  16. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–193
  17. Hosch W, Kristen AV, Libicher M, et al. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid. 2008;15(3):196–204
  18. Ruberg FL, Appelbaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009;103(4):544–549
  19. Migrino RQ, Phillips SA, Bright M, et al. Adverse functional significance of delayed enhancementon cardiac MRI in primary systemic amyloidosis. J Cardiovasc Magn Reson. 2008;10:A84
  20. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart. 2006;92(3):343–349
  21. Mabrua M, Dacher JN, Bauer F. Left ventricular hypertrophy: cardiac magnetic resonance may help differentiate amyloidosis from hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2010;103(1):55–56
  22. Fattori R, Rocchi G, Celletti F, et al. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J. 1998;136(5):824–830
  23. Maceira AM, Prasad SK, Hawkins PN, et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10:54
  24. Wassmuth R, Abdel-Aty H, Schulz-Menger J. Hypointense T2 signal predicts worse prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2010;12:P288
  25. Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. J Am Coll Cardiol Cardiovasc Imaging. 2009;2(12):1369–1377
  26. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58(6):1204–1211
  27. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103(1):253–258
  28. Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002;26(5):762–767
  29. Sharma OP. Diagnosis of cardiac sarcoidosis: an imperfect science, a hesitant art. Chest. 2003;123(1):18–19
  30. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21
  31. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. Arch Pathol Lab Med. 1995;119(2):167–172
  32. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83(6):315–334
  33. Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J. 2005;150(3):459–463
  34. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol. 2005;184(1):249–254
  35. Ichinose A, Otani H, Oikawa M, et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol. 2008;191(3):862–869
  36. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250–1258
  37. Smedema JP, Snoep G, Van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683–1690
  38. Manins V, Habersberger J, Pfluger H, et al. Cardiac magnetic resonance imaging in the evaluation of cardiac sarcoidosis: an Australian single-centre experience. Intern Med J. 2009;39(2):77–82
  39. Smedema JP, Snoep G, van Kroonenburgh MP, et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest. 2005;128(3):1629–1637
  40. Matoh F, Satoh H, Shiraki K, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol. 2008;51(3):179–188
  41. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122(6):1895–1901
  42. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969–1977
  43. Genée O, Fichet J, Alison D. Images in cardiovascular medicine: cardiac magnetic resonance imaging and eosinophilic endomyocardial fibrosis. Circulation. 2008;118(23):e710–e711
  44. Olsen EG. Restrictive cardiomyopathy. Postgrad Med J. 1986;62(728):607–608
  45. Puvaneswary M, Joshua F, Ratnarajah S. Idiopathic hypereosinophilic syndrome: magnetic resonance imaging findings in endomyocardial fibrosis. Australas Radiol. 2001;45(4):524–527
  46. Schneider U, Jenni R, Turina J, et al. Long-term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart. 1998;79(4):362–367
  47. Cockshott P, Saric S, Ikeme AC. Radiological findings in endomyocardial fibrosis. Circulation. 1967;35(5):913–922
  48. Deb K, Djavidani B, Bucher S, et al. Time course of eosinophilic myocarditis visualized by CMR. J Cardiovasc Magn Reson. 2008;10:21
  49. Lombardi C, Rusconi C, Faggiano P, et al. Successful reduction of endomyocardial fibrosis in a patient with idiopathic hypereosinophilic syndrome. A case report. Angiology. 1995;46(4):345–351
  50. Schneider U, Jenni R, Turina J, et al. Long term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart. 1998;79(4):362–367
  51. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193
  52. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051–2052
  53. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179
  54. Pennell DJ. T2∗ magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sc. 2005;1054:373–378
  55. Kondur AK, Li T, Vaitkevicius P, et al. Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2∗ and review of the literature. Clin Cardiol. 2009;32(6):E55–E59
  56. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744
  57. Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656
  58. Madhavan S, Sasidharan PK, Udayabhaskaran , et al. Restrictive cardiomyopathy due to primary plasma cell leukemia. J Assoc Physicians India. 2004;52(3):826–865
  59. Fujisaki J, Tanaka T, Kato J, et al. Primary cardiac lymphoma presenting clinically as restrictive cardiomyopathy. Circ J. 2005;69(2):249–252

PII: S0009-9260(11)00356-4

doi: 10.1016/j.crad.2011.05.020

Clinical Radiology
Volume 67, Issue 2 , Pages 95-105 , February 2012

Article Tools

* Image Usage & Resolution